Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Penciclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 8/20 | 0.47 |
| ▸ | PNP | P00491 | 9/20 | 0.47 |
| ▸ | TK1 | P04183 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Penciclovir SCHEMBL4240103 | 1.00 | HPRT1 (0.47) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Penciclovir SCHEMBL3494 | 0.95 | TK1 (0.49) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Penciclovir SCHEMBL15568622 | 0.89 | HPRT1 (0.42) | HPRT1PNPTK1MEN1ALDH1A1 | |
| SCHEMBL133681 | 0.88 | TK1 (0.43) | HPRT1PNPTK1MEN1ALDH1A1 | |
| SCHEMBL769982 | 0.88 | GAA (0.47) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Water SCHEMBL15532449 | 0.87 | TK1 (0.42) | HPRT1PNPTK1MEN1ALDH1A1 | |
| SCHEMBL15046000 | 0.85 | GAA (0.42) | HPRT1PNPTK1MEN1ALDH1A1 | |
| SCHEMBL15257623 | 0.84 | KMT2A (0.42) | HPRT1PNPTK1MEN1ALDH1A1 | |
| SCHEMBL15045959 | 0.84 | GAA (0.43) | HPRT1PNPTK1MEN1ALDH1A1 | |
| Tiviciclovir SCHEMBL15531845 | 0.83 | BLM (0.45) | HPRT1PNPTK1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101653603-B | Peptides and antibodies binding to anionic phospholipids and aminophospholipids and their use in treating disease | UNIV TEXAS | 2014-07-09 | — | — | CN | claimed |
| US-20100167268-A1 | SEROCONVERSION ASSAYS FOR DETECTING XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS | WHITTEMORE PETERSON INSTITUTE | 2010-07-01 | — | — | US | claimed |
| US-7611704-B2 | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-03 | — | — | US | claimed |
| US-7511124-B2 | Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-03-31 | — | — | US | claimed |
| US-7455833-B2 | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-11-25 | — | — | US | claimed |
| US-7384909-B2 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-10 | — | — | US | claimed |
| US-12281363-B2 | Methods for detecting antiviral-drug resistant virus | Secretary of State for Health and Social Care (GB) | 2025-04-22 | — | — | US | disclosed |
| CN-118846089-A | Solubilizing composition, application thereof and famciclovir tablet | 华农（肇庆）生物产业技术研究院有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-111377926-B | Penciclovir crystal form and preparation method thereof | 凯默斯医药科技(上海)有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2022159579-A2 | VARICELLA ZOSTER VIRUS LATERAL FLOW ASSAY | VIRO RESEARCH, LLC (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20210401846-A1 | MEDICAMENT, COMPOUND, COMPOSITION AND METHOD FOR TREATING HERPES | SAVESCU NAPOLEON (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210230710-A1 | METHODS FOR DETECTING ANTIVIRAL-DRUG RESISTANT VIRUS | Secretary of State for Health and Social Care (GB) | 2021-07-29 | — | — | US | disclosed |
| CN-109627243-B | Penciclovir-copper complex, synthetic method and application thereof | 广西壮族自治区水产科学研究院 | 2021-06-29 | — | — | CN | disclosed |
| WO-1997040193-A2 | METHOD FOR TYPING AND DETECTING HBV | INNOGENETICS N.V. (BE) | 1997-10-30 | — | — | WO | disclosed |
| US-5677308-A | Method for alleviating spasmodic torticollis | LERNER A MARTIN (US) | 1997-10-14 | — | — | US | disclosed |
| US-5674869-A | ADMINISTERING GUANINE DERIVATIVE; TREATMENT OF HIV AND HERPES VIRUS | BEECHAM GROUP PLC (GB) | 1997-10-07 | — | — | US | disclosed |
| EP-0538305-B1 | PENCICLOVIR AND FAMCICLOVIR AND RELATED GUANINE DERIVATIVES FOR THE TREATMENT OF THE HIV-1 INFECTIONS | BEECHAM GROUP PLC (GB) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996033720-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1996-10-31 | — | — | WO | disclosed |
| EP-0538305-A1 | PENCICLOVIR AND FAMCICLOVIR AND RELATED GUANINE DERIVATIVES FOR THE TREATMENT OF THE HIV-1 INFECTIONS. | BEECHAM GROUP PLC (GB) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000742-A1 | PENCICLOVIR AND FAMCICLOVIR AND RELATED GUANINE DERIVATIVES FOR THE TREATMENT OF THE HIV-1 INFECTIONS | BEECHAM GROUP PLC (GB) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401846-A1 | MEDICAMENT, COMPOUND, COMPOSITION AND METHOD FOR TREATING HERPES | SHBG, NEFM, HNMT | HPRT1 177/4885PNP 889/4885TK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.